YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BAAR, Switzerland, October 01, 2026--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable l…
BAAR, Switzerland, October 01, 2026--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management will host a conference…
NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what…
NovoCure (NVCR) is back in focus after the company confirmed that long-serving director Timothy Scannell retired from its board on September 2, 2026, following five years of service. The modest 0.85% 1 day share price return and 3.22% 7 da…
Novocure Limited NVCR recently disclosed that it identified unauthorized access to certain information systems through a subsidiary in mid-August 2026. Following detection, the company activated its cybersecurity response plan, implemented…
BAAR, Switzerland, September 02, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leona…
Shares of NovoCure (NVCR) have gained 18.1% over the past four weeks to close the last trading session at $17.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indicat…
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage…
Photo by Pexels on Pixabay The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price. When a company with a first-of-its-kind therapy for a large, underserved market gets hit b…
Shares of NovoCure (NVCR) have gained 13.6% over the past four weeks to close the last trading session at $17.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indicat…
The healthcare sector has quietly regained momentum in 2026, with the benchmark State Street Health Care Select Sector SPDR ETF (XLV) advancing 7.1% year to date as of Aug. 6. Investors have increasingly turned to the sector for its defens…
NovoCure (NVCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A c…
NovoCure (NVCR) closed the last trading session at $17.65, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price…
Have you evaluated the performance of NovoCure's (NVCR) international operations for the quarter ending June 2026? Given the extensive global presence of this oncology drug developer, analyzing the patterns in international revenues is cru…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. NovoCure (NVCR) drew fresh investor attention after raising its 2026 net revenue guidance to a range of US$710 million…
(RTTNews) - Today's top biotech gainers include Advanced Biomed, which led the rally with a gain of more than 200% over the past week. Novocure climbed following strong Q2 results and a revised full-year revenue outlook, while Medpace gain…
Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval for its brain therapy candidate. In…
Novocure stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment, Optune. Continue Reading
This article first appeared on GuruFocus. Net Revenue: $184 million, an increase of 16% year-over-year. Optune Geo Active Patient Growth: 11% year-over-year. Optune Lua Contribution: $5.4 million. Optune Pax Contribution: $1.6 million. Gro…
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This quarte…
Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany firs…
Major earnings expected before the bell on Thursday include: * Lockheed Martin Corporation (LMT [https://seekingalpha.com/symbol/LMT]) * RTX Corporation (RTX [https://seekingalpha.com/symbol/RTX]) * Nokia Oyj (NOK [https://seekingalpha.com…
Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings pictu…
[Rolled newspaper with the headline Quarterly Results] Zerbor As earnings season enters a pivotal week, investors will be watching a broad lineup of market leaders across technology, telecommunications, industrials, aerospace and defense,…
Wall Street expects a year-over-year increase in earnings on higher revenues when NovoCure (NVCR) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings pic…
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@p…
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@p…
NovoCure Limited NVCR recently announced that its portable medical device, Option Pax, has received the CE (Conformité Européenne) mark for treating adult patients with locally advanced pancreatic cancer of exocrine origin. The non-invasiv…
BAAR, Switzerland, July 01, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call…
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@p…
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel Treatme…
Investors choosing between high-growth healthcare innovators must weigh specialized diagnostics against therapeutic platforms. Choosing between HeartFlow Inc. (NASDAQ:HTFL) and NovoCure Ltd. (NASDAQ:NVCR) depends on your appetite for risk…
Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique scientific approaches. NovoCure is establi…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. NovoCure (NVCR) drew investor attention after releasing topline Pha…
Key Points Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor…
The S&P 500 Index ($SPX) (SPY) on Thursday closed up +1.08%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.48%. September E-mini S&P futures (ESU26) rose +1.15%, and Se…